ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2347

Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
Abstract Number: 1316

Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Abstract Number: 2046

Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents
Abstract Number: 1727

Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab
Abstract Number: 2138

DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis
Abstract Number: 0897

Dynamic eQTLs from Activated Human B Cells Suggest Cell-state Dependent Effects for GWAS Risk Variants in BLK
Abstract Number: 2669

Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Abstract Number: 1496

Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Abstract Number: 1165

Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 0076

Early (3-Month) and Maintained (12-Month) Comparative Effectiveness of 5 Different Classes of Advanced Therapies in a Large Multinational Cohort of Real-World PsA Patients
Abstract Number: 1717

Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Abstract Number: 1682

Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor
Abstract Number: 1346

Early Diagnosis of Rheumatoid Arthritis: Role of Joint Ultrasound Assessment
Abstract Number: 0601

Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Abstract Number: 0667

Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].